Data Sheet (Cat.No.T41291)

TargetMol

MS-PPOH

Chemical Properties



CAS No. : 206052-02-0

Formula: C16H21NO4S

Molecular Weight: 323.41

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	MS-PPOH is a potent and selective inhibitor of cytochrome P450 (CYP) epoxygenase, specifically inhibiting CYP2C8 and CYP2C9 with IC50 values of 15 and 11 μM,
Targets(IC50)	Cytochromes P450
In vitro	MS-PPOH inhibits cellular EET synthesis, tonic (basal) cell invasion, and migration, and reduces the 11,12-EET (1.0 μM)-induced cell motility [1].
In vivo	Intravenous administration of MS-PPOH (20 mg/kg/day) for 6 days significantly reduced renal levels of epoxyeicosatrienoic acids (EETs) in Dahl salt-resistant rats on a 2% NaCl drinking solution [3].

Solubility Information

Solubility	DMSO: 65 mg/mL (200.98 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (15.46 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.0921 mL	15.4603 mL	30.9205 mL
5 mM	0.6184 mL	3.0921 mL	6.1841 mL
10 mM	0.3092 mL	1.546 mL	3.0921 mL
50 mM	0.0618 mL	0.3092 mL	0.6184 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Kasem Nithipatikom, et al. Inhibition of carcinoma cell motility by epoxyeicosatrienoic acid (EET) antagonists. Cancer Sci. 2010 Dec;101(12):2629-36.
Jun Yang, et al. Cytochrome P450 2C24: Expression, Tissue Distribution, High-Throughput Assay, and Pharmacological Inhibition. Acta Pharm Sin B. 2012 Apr;2(2):137-145.
Jing Li, et al. Pharmacological manipulation of arachidonic acid-epoxygenase results in divergent effects on renal damage. Front Pharmacol. 2014 Aug 15;5:187.